LLY Has Strong Product Pipeline

Analyst John Boris of Citi Investment Research and Analysis maintains his "buy" rating on Eli Lilly (NYSE: LLY). The target price for LLY is set to $41.

Eli Lilly has reported its 2010 EPS guidance short of the estimates and the consensus. It should be remembered, however, that LLY had raised its guidance by 2% in 2008 and by 5% in 2009. LLY has indicated that it would fund its dividend even in a worst case scenario. The analyst believes that the company’s pipeline products would add immense value to its stock.

According to Citi Investment Research and Analysis, the company’s Life-Cycle Management Oppys and innovative pipeline appear underappreciated. LLY’s assets are very innovative and offer an attractive risk/reward.